Prostate
Cancer

Oncology Solutions

One in seven men will be diagnosed with prostate cancer,1 with 1.2 million new cases in 2018.2 According to the American Cancer Society the overall 5-year survival rate is 99 percent for all stages of prostate cancer, however when diagnosed at stage IVB, the 5-year survival rate drops significantly to 29 percent.3


The Patient Journey

  • Early Detection

    SIGNA™ Artist AIR™ Edition

    SIGNA™ Artist AIR™ Edition, GE Healthcare’s p...
  • Diagnosis

    SIGNA™ Architect AIR™ Edition

    SIGNA™ Architect AIR™ Edition, GE Healthcare’s premium 3.0T, 70 cm wide bore MR system, leverages intelligent scanning technology to enable patient-friendly exams with ...

  • Staging

    Computed Tomography

    Your need for quality patient care at low dose with greater productivity and affordability is more important than ever.  That’s why we design CT syst...
  • Treatment Planning

    Discovery RT

    Discovery RT is a comprehensive radiation therapy solution that allows you to see all that your CT can see.
  • Therapy and Monitoring

    SIGNA™ PET/MR with QuantWorks – 60cm

    Introducing SIGNA™ PET/MR with QuantWorks. Built with pioneering TOF and integrated with a 3.0T MR, its impressive quantitative accuracy and high count rate combined with ...
  • Follow up

    LOGIQ™ E10 Ultrasound Series

    Next-generation, leadership ultrasound that adapts to your needs, today and into the future.

The latest in Oncology


1. Prostate Cancer Risk Factors [Internet]. WebMD. 2018 [cited 5 November 2018]. Available from: https://www.webmd.com/prostate-cancer/guide/prostate-cancer-risk-factors
2. Prostate cancer statistics [Internet]. World Cancer Research Fund. 2018 [cited 5 November 2018]. Available from: https://www.wcrf.org/dietandcancer/cancer-trends/prostate-cancer-statistics
3. Survival Rates for Prostate Cancer [Internet]. Cancer.org. 2018 [cited 5 November 2018]. Available from: https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html#written_by Patel AR, Klein EA.